Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 376,832,160
  • Shares Outstanding, K 1,768,169
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 24,061 M
  • 60-Month Beta 0.34
  • Price/Sales 6.05
  • Price/Cash Flow 13.82
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 32.50% (-1.28%)
  • Historical Volatility 25.70%
  • IV Percentile 90%
  • IV Rank 42.80%
  • IV High 51.27% on 04/08/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 2) 4.65 (2.15%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 5,136
  • Volume Avg (30-Day) 12,706
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 225,304
  • Open Int (30-Day) 231,430
  • Expected Range 211.57 to 220.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.01
  • Number of Estimates 10
  • High Estimate 3.17
  • Low Estimate 2.97
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.80 +7.52%
on 03/24/26
237.11 -8.49%
on 03/04/26
-15.10 (-6.51%)
since 02/27/26
3-Month
201.80 +7.52%
on 03/24/26
237.11 -8.49%
on 03/04/26
-13.00 (-5.65%)
since 12/26/25
52-Week
164.39 +31.99%
on 04/09/25
244.81 -11.37%
on 10/01/25
+11.69 (+5.69%)
since 03/28/25

Most Recent Stories

More News
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

IRVINE, Calif. , March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting ® , the...

ABBV : 216.26 (+1.47%)
AbbVie to Host First-Quarter 2026 Earnings Conference Call

NORTH CHICAGO, Ill. , March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will...

ABBV : 216.26 (+1.47%)
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)

- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid onset and a consistently favorable safety profile across studied patient populations

ABBV : 216.26 (+1.47%)
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

NORTH CHICAGO, Ill. , March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology...

ABBV : 216.26 (+1.47%)
Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

- Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines (as early as 8 hours), robust and consistent efficacy,...

ABBV : 216.26 (+1.47%)
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

NORTH CHICAGO, Ill. , March 26, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM ®...

ABBV : 216.26 (+1.47%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 66.45 (-0.85%)
AAPL : 248.43 (+0.73%)
AVGO : 300.69 (+2.48%)
CVX : 212.16 (+0.69%)
VZ : 49.79 (-1.01%)
$SPX : 6,425.81 (+1.29%)
JPM : 289.14 (+1.89%)
JNJ : 243.36 (+0.36%)
SCHD : 30.62 (+0.46%)
ABBV : 216.26 (+1.47%)
BMY : 60.17 (+0.74%)
MSFT : 364.06 (+1.42%)
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results

ABBV : 216.26 (+1.47%)
Quiet Outperformance From an Overlooked Dividend ETF

DGRO may stand out for investors looking for an ETF focused not only on the highest dividend yields, but on quality dividend payers likely to be stable.

AAPL : 248.43 (+0.73%)
VIG : 212.61 (+0.91%)
XOM : 173.68 (+1.29%)
JNJ : 243.36 (+0.36%)
ABBV : 216.26 (+1.47%)
DGRO : 69.52 (+0.78%)
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

NORTH CHICAGO, Ill. , March 9, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results 1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating...

ABBV : 216.26 (+1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 217.61
2nd Resistance Point 215.77
1st Resistance Point 214.45
Last Price 216.26
1st Support Level 211.29
2nd Support Level 209.45
3rd Support Level 208.13

See More

52-Week High 244.81
Last Price 216.26
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.